GlassScriptPhysician profile
Zully E Ambroise
NPI 1316167083
$3,745.50
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $365 · 2021: $427 · 2022: $530 · 2023: $613 · 2024: $518 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.61 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $625.43 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $516.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $493.49 | 2019-2023 | Pediarix, Bexsero, Rotarix |
| Tris Pharma INC | $375.83 | 2019-2024 | Dyanavel Xr, Onyda Xr |
| Collegium Pharmaceutical, INC. | $240.49 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $220.94 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $176.22 | 2019-2024 | Jornay Pm |
| Corium, LLC | $171.89 | 2021-2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $149.60 | 2024-2025 | |
| Genentech USA, INC. | $146.15 | 2020 | |
| Merck Sharp & Dohme LLC | $128.87 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Alk-Abello, INC | $111.52 | 2023 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $75.44 | 2020-2022 | |
| Sanofi Pasteur INC. | $73.90 | 2019-2024 | |
| Adlon Therapeutics L.P. | $69.77 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $46.73 | 2025 | Neffy |
| Phadia US INC. | $44.97 | 2021-2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $24.76 | 2024 | Ycanth |
| Photonicare INC | $24.26 | 2023 | Otosight Middle Ear Scope |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zully Ambroise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.